步長製藥(603858.SH)擬放棄優先受讓投資基金份額
格隆匯2月25日丨步長製藥(603858.SH)公佈,公司作爲有限合夥人蔘與認購投資的投資基金元禾璞華有限合夥人長三角協同優勢產業股權投資合夥企業(有限合夥)擬將其未實繳的5,000萬元基金份額以0元的價格轉讓給廣州東進荔創,擬將其未實繳的3,000萬元基金份額以0元的價格轉讓給樑溪科創投資,擬將其未實繳的2,000萬元基金份額以0元的價格轉讓給寧波泓寧亨泰;有限合夥人蘇州市創新產業發展引導基金(有限合夥)擬將其未實繳的5,000萬元基金份額以0元的價格轉讓給上海引領接力。公司同意放棄優先受讓權。此外,投資基金部分有限合夥人合計擬減少未實繳出資1.31億元,減資完成後,投資基金總認繳規模擬由42.58億元變更爲41.27億元。上述份額轉讓、減資完成後,公司認繳元禾璞華5,000萬元基金份額不變,公司持有的元禾璞華基金份額比例將由1.17%變更爲1.21%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.